[go: up one dir, main page]

WO2002046194A3 - Imidazopyridines substituees - Google Patents

Imidazopyridines substituees Download PDF

Info

Publication number
WO2002046194A3
WO2002046194A3 PCT/US2001/046915 US0146915W WO0246194A3 WO 2002046194 A3 WO2002046194 A3 WO 2002046194A3 US 0146915 W US0146915 W US 0146915W WO 0246194 A3 WO0246194 A3 WO 0246194A3
Authority
WO
WIPO (PCT)
Prior art keywords
useful
compounds
substituted imidazopyridines
biosynthesis
induce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/046915
Other languages
English (en)
Other versions
WO2002046194A2 (fr
Inventor
Kyle J Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA2003042937A priority Critical patent/UA74593C2/uk
Priority to HR20030465A priority patent/HRP20030465A2/hr
Priority to SK714-2003A priority patent/SK7142003A3/sk
Priority to EP01987315A priority patent/EP1343783A2/fr
Priority to IL15588501A priority patent/IL155885A0/xx
Priority to NZ526085A priority patent/NZ526085A/xx
Priority to HK04106187.6A priority patent/HK1063466B/xx
Priority to AU2002239547A priority patent/AU2002239547B2/en
Priority to CA002431040A priority patent/CA2431040A1/fr
Priority to PL01365739A priority patent/PL365739A1/xx
Priority to KR10-2003-7007533A priority patent/KR20030070048A/ko
Priority to MXPA03005013A priority patent/MXPA03005013A/es
Priority to EEP200300273A priority patent/EE200300273A/xx
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to AU3954702A priority patent/AU3954702A/xx
Priority to HU0600592A priority patent/HUP0600592A2/hu
Priority to BR0116034-6A priority patent/BR0116034A/pt
Priority to JP2002547931A priority patent/JP2004525868A/ja
Publication of WO2002046194A2 publication Critical patent/WO2002046194A2/fr
Publication of WO2002046194A3 publication Critical patent/WO2002046194A3/fr
Priority to NO20032453A priority patent/NO20032453L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des composés d'imidazopyridine renfermant une fonctionnalité amine substituée en position 1. Ces composés sont utiles comme modificateurs de la réponse immune. Les composés et compositions selon l'invention peuvent induire la biosynthèse de différentes cytokines et sont utiles dans le traitement d'une palette de pathologies, notamment des maladies virales et néoplastiques.
PCT/US2001/046915 2000-12-08 2001-12-06 Imidazopyridines substituees Ceased WO2002046194A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
UA2003042937A UA74593C2 (en) 2000-12-08 2001-06-12 Substituted imidazopyridines
MXPA03005013A MXPA03005013A (es) 2000-12-08 2001-12-06 Imidazopiridinas sustituidas.
EP01987315A EP1343783A2 (fr) 2000-12-08 2001-12-06 Imidazopyridines substituees
IL15588501A IL155885A0 (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
NZ526085A NZ526085A (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
HK04106187.6A HK1063466B (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
AU2002239547A AU2002239547B2 (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
CA002431040A CA2431040A1 (fr) 2000-12-08 2001-12-06 Imidazopyridines substituees
PL01365739A PL365739A1 (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
HR20030465A HRP20030465A2 (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
EEP200300273A EE200300273A (et) 2000-12-08 2001-12-06 Asendatud imidasopüridiinid
SK714-2003A SK7142003A3 (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
KR10-2003-7007533A KR20030070048A (ko) 2000-12-08 2001-12-06 치환 이미다조피리딘
AU3954702A AU3954702A (en) 2000-12-08 2001-12-06 Substituted imidazopyridines
HU0600592A HUP0600592A2 (en) 2000-12-08 2001-12-06 Substituted imidazopyridines, pharmaceutical compositions containing them and intermediates
BR0116034-6A BR0116034A (pt) 2000-12-08 2001-12-06 Imidazopiridinas substituìdas
JP2002547931A JP2004525868A (ja) 2000-12-08 2001-12-06 置換イミダゾピリジン類
NO20032453A NO20032453L (no) 2000-12-08 2003-05-28 Substituerte imidazopyridiner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25422800P 2000-12-08 2000-12-08
US60/254,228 2000-12-08

Publications (2)

Publication Number Publication Date
WO2002046194A2 WO2002046194A2 (fr) 2002-06-13
WO2002046194A3 true WO2002046194A3 (fr) 2003-02-06

Family

ID=22963437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046915 Ceased WO2002046194A2 (fr) 2000-12-08 2001-12-06 Imidazopyridines substituees

Country Status (23)

Country Link
EP (1) EP1343783A2 (fr)
JP (1) JP2004525868A (fr)
KR (1) KR20030070048A (fr)
CN (1) CN1249062C (fr)
AR (1) AR035670A1 (fr)
AU (2) AU3954702A (fr)
BR (1) BR0116034A (fr)
CA (1) CA2431040A1 (fr)
CZ (1) CZ20031593A3 (fr)
EE (1) EE200300273A (fr)
HR (1) HRP20030465A2 (fr)
HU (1) HUP0600592A2 (fr)
IL (1) IL155885A0 (fr)
MX (1) MXPA03005013A (fr)
NO (1) NO20032453L (fr)
NZ (1) NZ526085A (fr)
PL (1) PL365739A1 (fr)
RU (1) RU2294934C2 (fr)
SK (1) SK7142003A3 (fr)
TW (1) TWI243819B (fr)
UA (1) UA74593C2 (fr)
WO (1) WO2002046194A2 (fr)
ZA (1) ZA200305238B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030129B2 (en) 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US7612083B2 (en) 2000-12-08 2009-11-03 Coley Pharmaceutical Group, Inc. Urea substituted imidazoquinoline ethers
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20020107262A1 (en) * 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
CA2467828C (fr) 2001-11-29 2011-10-04 3M Innovative Properties Company Formulations pharmaceutiques comprenant un modificateur de reponse immunitaire
CA2365732A1 (fr) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Etalonnages
EP1511746A2 (fr) * 2002-05-29 2005-03-09 3M Innovative Properties Company Procede permettant d'obtenir des imidazo[4,5-c]pyridin-4-amines
KR101088615B1 (ko) 2002-08-15 2011-11-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 면역자극 조성물 및 면역 반응을 자극하는 방법
WO2004028539A2 (fr) * 2002-09-26 2004-04-08 3M Innovative Properties Company Dimeres 1h-imidazo
MXPA05006740A (es) 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
EP2572715A1 (fr) 2002-12-30 2013-03-27 3M Innovative Properties Company Combinaisons immunostimulantes
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
EP1601365A4 (fr) 2003-03-04 2009-11-11 3M Innovative Properties Co Traitement prophylactique de la neoplasie epidermique induite par les uv
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
CA2518282C (fr) 2003-03-13 2012-11-06 3M Innovative Properties Company Procedes pour ameliorer la qualite de la peau
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
JP2006522823A (ja) 2003-04-10 2006-10-05 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調節物質化合物の送達
WO2004110991A2 (fr) 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESSUS DE PREPARATION D'IMIDAZO[4,5-c]PYRIDINE-4-AMINES
JP2007502288A (ja) 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ含有化合物
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2537763A1 (fr) 2003-09-05 2005-03-17 3M Innovative Properties Company Traitement pour le lymphome a cellules b cd5<sp>+</sp>
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
CA2545825A1 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitue par hydroxylamine
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
JP2007513165A (ja) 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法
US7888349B2 (en) 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
WO2005066170A1 (fr) 2003-12-29 2005-07-21 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (fr) 2004-06-15 2005-12-29 3M Innovative Properties Company Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
CA2594674C (fr) 2004-12-30 2016-05-17 3M Innovative Properties Company Composes chiraux [1,2]imidazo[4,5-c] substitues a noyau fusionne
EP1844201B1 (fr) 2005-02-04 2016-08-24 3M Innovative Properties Company Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2623541A1 (fr) * 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. Procede de preparation de 1h-imidazo[4,5-c]pyridines et d'analogues de ceux-ci
CN100344325C (zh) * 2005-10-17 2007-10-24 华南师范大学 一种治疗宫颈癌的药物及其制备方法与应用
WO2008008432A2 (fr) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Composés à cycle [1,2] imidazo [4,5-c] fusionné chiral substitué et procédés correspondants
WO2009034411A1 (fr) * 2007-09-12 2009-03-19 Centre National De La Recherche Scientifique Perharidines en tant qu'inhibiteurs de cdk
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
BR112016012243A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
EP3092256B1 (fr) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Composés et compositions pour l'immunothérapie
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
WO2018232725A1 (fr) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Compositions pharmaceutiques

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5494916A (en) * 1993-07-15 1996-02-27 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]pyridin-4-amines
EP0894797A1 (fr) * 1997-01-09 1999-02-03 Terumo Kabushiki Kaisha Nouveaux derives d'amide et intermediaires utilises pour leur synthese
WO1999029693A1 (fr) * 1997-12-11 1999-06-17 Minnesota Mining And Manufacturing Company Imidazonaphthyridines et leur utilisation dans l'activation de la biosynthese de cytokines
WO2000076519A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees sulfonamide et sulfamide
WO2000076505A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees amides
WO2000076518A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees par uree

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DE69229114T2 (de) * 1991-03-01 1999-11-04 Minnesota Mining And Mfg. Co., Saint Paul 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5494916A (en) * 1993-07-15 1996-02-27 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]pyridin-4-amines
EP0894797A1 (fr) * 1997-01-09 1999-02-03 Terumo Kabushiki Kaisha Nouveaux derives d'amide et intermediaires utilises pour leur synthese
WO1999029693A1 (fr) * 1997-12-11 1999-06-17 Minnesota Mining And Manufacturing Company Imidazonaphthyridines et leur utilisation dans l'activation de la biosynthese de cytokines
WO2000076519A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees sulfonamide et sulfamide
WO2000076505A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees amides
WO2000076518A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees par uree

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612083B2 (en) 2000-12-08 2009-11-03 Coley Pharmaceutical Group, Inc. Urea substituted imidazoquinoline ethers
US7030129B2 (en) 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines

Also Published As

Publication number Publication date
CN1249062C (zh) 2006-04-05
AR035670A1 (es) 2004-06-23
JP2004525868A (ja) 2004-08-26
BR0116034A (pt) 2004-08-03
CZ20031593A3 (cs) 2004-01-14
PL365739A1 (en) 2005-01-10
HRP20030465A2 (en) 2004-06-30
NZ526085A (en) 2004-12-24
EP1343783A2 (fr) 2003-09-17
MXPA03005013A (es) 2003-09-05
IL155885A0 (en) 2003-12-23
NO20032453L (no) 2003-07-16
RU2003116648A (ru) 2005-02-10
ZA200305238B (en) 2004-08-27
AU2002239547B2 (en) 2006-11-30
KR20030070048A (ko) 2003-08-27
SK7142003A3 (en) 2003-10-07
TWI243819B (en) 2005-11-21
EE200300273A (et) 2004-02-16
WO2002046194A2 (fr) 2002-06-13
CA2431040A1 (fr) 2002-06-13
RU2294934C2 (ru) 2007-03-10
HK1063466A1 (en) 2004-12-31
HUP0600592A2 (en) 2006-11-28
NO20032453D0 (no) 2003-05-28
CN1478090A (zh) 2004-02-25
AU3954702A (en) 2002-06-18
UA74593C2 (en) 2006-01-16

Similar Documents

Publication Publication Date Title
WO2002046194A3 (fr) Imidazopyridines substituees
WO2002046190A3 (fr) Imidazoquinolines substituees sulfamido ether
WO2003050119A3 (fr) Imidazopyridines a substitution uree
IL146468A0 (en) Amide substituted imidazoquinolines
MXPA04005362A (es) Imidazoquinolinas sustituidas con tioeter.
WO2004028539A3 (fr) Dimeres 1h-imidazo
WO2005003064A3 (fr) Imidazo-quinolines a substitution sulfonamide
IL146486A0 (en) Sulfonamide and sulfamide susbtituted imidazoquinolines
HK1047224A1 (zh) 尿素取代的咪唑喹啉
NO20045445L (no) Etersubstituerte imidazopyridiner
GB2390811B (en) Therapeutic compositions that alter the immune response
GB0514967D0 (en) Therapeutic compositions that alter the immune response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 155885

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526085

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 018198570

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005013

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037007533

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 7142003

Country of ref document: SK

Ref document number: PV2003-1593

Country of ref document: CZ

Ref document number: 2431040

Country of ref document: CA

Ref document number: 1-2003-500487

Country of ref document: PH

Ref document number: 2002547931

Country of ref document: JP

Ref document number: 2002239547

Country of ref document: AU

Ref document number: 890/CHENP/2003

Country of ref document: IN

Ref document number: P20030465A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2003/05238

Country of ref document: ZA

Ref document number: 200305238

Country of ref document: ZA

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 2001987315

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037007533

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001987315

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1593

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 526085

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526085

Country of ref document: NZ